Segment Reporting - Schedule of Operating Segment (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($) segment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2025 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	1
Number of operating segments | segment	1
Revenues
Total revenues	$ 407,320	$ 333,615	$ 124,456
Less
Cost of sales	39,537	50,556	17,795
Total costs and operating expenses	448,297	361,565	187,732
Loss before provision for income taxes	(60,630)	(38,870)	(65,520)
Net loss	(61,599)	(39,136)	(66,067)
AstraZeneca | AZ Termination Agreement
Less
Maximum potential payment per agreement				$ 75,000
Reportable Segment
Revenues
Total revenues	407,320	333,615	124,456
Less
Research and development	58,429	39,480	29,231
Selling expenses	226,925	162,957	80,028
General and administrative	58,662	52,916	34,020
Stock-based compensation	48,962	37,381	13,530
Other segment expenses	15,782	18,275	13,128
Total costs and operating expenses	448,297	361,565	187,732
Loss before provision for income taxes	(40,977)	(27,950)	(63,276)
Other reconciliation items	(20,622)	(11,186)	(2,791)
Net loss	(61,599)	(39,136)	(66,067)
Allocated facilities, information technology, and human resources	14,800	16,900	12,300
Product sales, net
Revenues
Total revenues	377,808	319,196	82,526
Product sales, net | Reportable Segment
Revenues
Total revenues	377,808	319,196	82,526
Less
Cost of sales	11,185	6,851	2,323
Other cost of revenue | Reportable Segment
Revenues
Total revenues	29,512	14,419	41,930
Less
Cost of sales	$ 28,352	$ 43,705	$ 15,472